Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
354 Leser
Artikel bewerten:
(2)

Gorayeb & Associates, P.C.: Christopher Gorayeb Champions Equity and Diversity at Bates College

Finanznachrichten News

Gorayeb & Associates Founder Leads Initiatives to Support Marginalized and Undocumented Students at His Alma Mater

NEW YORK, NY / ACCESSWIRE / May 9, 2024 / Gorayeb & Associates is proud to highlight the philanthropic efforts of its founder, Christopher Gorayeb, a Bates College alumnus who has significantly contributed to promoting equity, diversity, and financial aid for students from marginalized backgrounds, including undocumented students, at his alma mater, Bates College.

Christopher Gorayeb at Bates College

Christopher Gorayeb at Bates College
Christopher Gorayeb, founder of Gorayeb & Associates, stands outside Bates College, highlighting his dedication to fostering equity and diversity through initiatives that support marginalized and undocumented students.

Christopher Gorayeb, who graduated in 1980 and later served on the board of trustees for 15 years, has been a driving force behind several initiatives aimed at enhancing the educational experience for students facing systemic barriers. His establishment of The Gorayeb Family Fund for Equity and Diversity in 2017 marks a cornerstone in Bates College's efforts to promote equity and inclusion. The fund annually supports diversity programs and events, including providing winter clothing for students in need and establishing a dedicated campus space for marginalized students to access resources and build community.

For a detailed overview of The Gorayeb Family's impact, visit: Bates College Campaign News.

Elevating his commitment, in 2021, Gorayeb pledged his support to The Schuler Access Initiative, targeting Pell-eligible students and low-income and undocumented students. The Schuler Access Initiative matched contributions from Bates donors like Gorayeb, funneling a $70 million boost into financial aid for undocumented and Pell-eligible students at Bates.

Discover more about this transformative initiative: The Schuler Access Initiative at Bates.

Christopher Gorayeb's philanthropic endeavors at Bates College reflect a deep-seated belief in the power of education to transform lives and break down systemic barriers. His work exemplifies a broader mission of social responsibility and advocacy, mirroring the values he embodies through his leadership at Gorayeb & Associates. The firm, known for its vigorous defense of construction accident victims, extends its commitment to justice and community support, underscoring a holistic approach to making a difference in society.

About Gorayeb & Associates:

Gorayeb & Associates, a leading New York law firm founded by Christopher Gorayeb, specializes in personal injury and construction accident cases. The firm is renowned for its unwavering commitment to advocating for the rights and well-being of workers and their families. Parallel to its legal endeavors, Gorayeb & Associates is actively involved in community outreach and philanthropic efforts, aimed at creating equitable opportunities and fostering a more inclusive society.

Contact Information

Ian Jorge Miller
imiller@gorayeb.com
212-267-9222

SOURCE: Gorayeb & Associates

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.